Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition–An Outstanding Challenge
Back in 1995, a landmark paper was published, which shaped the fibrosis literature for many years to come. During the characterization of a fibroblast-specific marker (FSP1) in the kidneys, an observation was made, which gave rise to the hypothesis that “fibroblasts in some cases arise from the loca...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-04-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.00388/full |
| _version_ | 1818284265428746240 |
|---|---|
| author | Attila Fintha Ákos Gasparics László Rosivall Attila Sebe Attila Sebe |
| author_facet | Attila Fintha Ákos Gasparics László Rosivall Attila Sebe Attila Sebe |
| author_sort | Attila Fintha |
| collection | DOAJ |
| description | Back in 1995, a landmark paper was published, which shaped the fibrosis literature for many years to come. During the characterization of a fibroblast-specific marker (FSP1) in the kidneys, an observation was made, which gave rise to the hypothesis that “fibroblasts in some cases arise from the local conversion of epithelium.” In the following years, epithelial-mesenchymal transition was in the spotlight of fibrosis research, especially in the kidney. However, the hypothesis came under scrutiny following some discouraging findings from lineage tracing experiments and clinical observations. In this review, we provide a timely overview of the current position of the epithelial-mesenchymal transition hypothesis in the context of fibrosis (with a certain focus on renal fibrosis) and highlight some of the potential hurdles and pitfalls preventing therapeutic breakthroughs targeting fibrotic epithelial-mesenchymal transition. |
| first_indexed | 2024-12-13T00:50:03Z |
| format | Article |
| id | doaj.art-3739c326420c4a16a2d0f010764a7445 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-13T00:50:03Z |
| publishDate | 2019-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-3739c326420c4a16a2d0f010764a74452022-12-22T00:04:56ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-04-011010.3389/fphar.2019.00388440118Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition–An Outstanding ChallengeAttila Fintha0Ákos Gasparics1László Rosivall2Attila Sebe3Attila Sebe42nd Department of Pathology, Semmelweis University, Budapest, Hungary1st Department of Obstetrics and Gynecology, Semmelweis University, Budapest, HungaryDepartment of Pathophysiology, International Nephrology Research and Training Center, Semmelweis University, Budapest, HungaryDepartment of Pathophysiology, International Nephrology Research and Training Center, Semmelweis University, Budapest, HungaryDivision of Medical Biotechnology, Paul Ehrlich Institute, Langen, GermanyBack in 1995, a landmark paper was published, which shaped the fibrosis literature for many years to come. During the characterization of a fibroblast-specific marker (FSP1) in the kidneys, an observation was made, which gave rise to the hypothesis that “fibroblasts in some cases arise from the local conversion of epithelium.” In the following years, epithelial-mesenchymal transition was in the spotlight of fibrosis research, especially in the kidney. However, the hypothesis came under scrutiny following some discouraging findings from lineage tracing experiments and clinical observations. In this review, we provide a timely overview of the current position of the epithelial-mesenchymal transition hypothesis in the context of fibrosis (with a certain focus on renal fibrosis) and highlight some of the potential hurdles and pitfalls preventing therapeutic breakthroughs targeting fibrotic epithelial-mesenchymal transition.https://www.frontiersin.org/article/10.3389/fphar.2019.00388/fullepithelial to mesenchymal transitionfibrosismyofibroblastrepairchronic injury |
| spellingShingle | Attila Fintha Ákos Gasparics László Rosivall Attila Sebe Attila Sebe Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition–An Outstanding Challenge Frontiers in Pharmacology epithelial to mesenchymal transition fibrosis myofibroblast repair chronic injury |
| title | Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition–An Outstanding Challenge |
| title_full | Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition–An Outstanding Challenge |
| title_fullStr | Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition–An Outstanding Challenge |
| title_full_unstemmed | Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition–An Outstanding Challenge |
| title_short | Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition–An Outstanding Challenge |
| title_sort | therapeutic targeting of fibrotic epithelial mesenchymal transition an outstanding challenge |
| topic | epithelial to mesenchymal transition fibrosis myofibroblast repair chronic injury |
| url | https://www.frontiersin.org/article/10.3389/fphar.2019.00388/full |
| work_keys_str_mv | AT attilafintha therapeutictargetingoffibroticepithelialmesenchymaltransitionanoutstandingchallenge AT akosgasparics therapeutictargetingoffibroticepithelialmesenchymaltransitionanoutstandingchallenge AT laszlorosivall therapeutictargetingoffibroticepithelialmesenchymaltransitionanoutstandingchallenge AT attilasebe therapeutictargetingoffibroticepithelialmesenchymaltransitionanoutstandingchallenge AT attilasebe therapeutictargetingoffibroticepithelialmesenchymaltransitionanoutstandingchallenge |